Locus pulls in a modest Series B as it attempts to emulate oncology's precision medicine model in antibacterials

Despite a significant bear market affecting the public biotech sector, private companies are still managing to pull in VC-backed funding rounds. The latest such round comes out of North Carolina’s research triangle for a precision antibacterial drug maker.